Business Wire

MA-WHOOP

Share
WHOOP Announces Its “Year In Review” Celebrating That 2023 Was the Year Human Performance Became a Lifestyle

WHOOP, the human performance company, today released its annual Year in Review, highlighting the ways members unlocked their healthy obsessions in 2023, and identifies health and wellness patterns for 2024. The WHOOP community increased its commitment to their overall health and fitness and gained invaluable insights across Sleep, Strain, Recovery, and Stress, as WHOOP turns a dynamic understanding of the body into a healthy obsession, made possible by its latest innovations including Stress Monitor, Strength Trainer, and WHOOP Coach.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211786571/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

WHOOP announces its “Year In Review” celebrating that 2023 was the year human performance became a lifestyle. (Photo: Business Wire)

The past year revealed that the biggest trends in health and wellbeing were centered on lifestyle shifts aiming to optimize performance. From changes in alcohol consumption, to the rise of new recovery behaviors like ice baths and red light therapy, 2023 saw an influx of circadian, nutritional, longevity, and health promoting habits. WHOOP data shows that even the smallest behavioral changes can have a big impact on the body and mind.

“‘Year in Review’ is one of our favorite features to launch each year,” said Will Ahmed, Founder and CEO of WHOOP. “It's an important way to celebrate our members’ accomplishments and reflect on changing trends around the world.”

Recovery - The best new buzz comes from ice baths, not booze.

  • Alcohol consumption is down. WHOOP members consumed alcohol less frequently in 2023, but when they did, they consumed more, with an average of three drinks per sitting.
  • Ice baths for recovery have shown a strong increase in popularity, as they can help reduce muscle soreness after intense workouts, aid in recovery by constricting blood vessels and decreasing metabolic activity. They may also release endorphins that can improve mood and energy.
  • Red light therapy was also popular with the WHOOP community and helps improve Recovery as it’s believed that red light may increase production of melatonin, ultimately enhancing sleep.
  • A strong Recovery is simple. There’s no need for elaborate Recovery routines or the latest gadgets. Behaviors that helped Recovery this year include strong sleep performance, consuming caffeine and implementing consistent wake times. Behaviors that hinder Recovery are consuming alcohol, having a fever, or excessive Strain.
  • Sex and Recovery: Engaging in sexual activity can contribute to Recovery by reducing stress through the release of endorphins and oxytocin, which may help lower cortisol levels and promote relaxation, potentially leading to improved Recovery scores.
    • The countries where WHOOP members had the most sex in 2023: U.S., Australia, Canada, Denmark, Netherlands
    • Within the U.S., the states where members have the most sex are: Utah, Oklahoma, Alabama, Idaho, Nevada
  • Stress can negatively impact recovery by increasing resting heart rate (RHR) and decreasing heart rate variability (HRV), key indicators WHOOP uses to calculate the Recovery score. Modalities such as breathwork and meditation are top ways WHOOP members managed stress this year.

Sleep Hygiene - less can be more, when quality is enhanced.

In 2023, WHOOP members didn’t get more sleep, but they found ways to get better sleep.

  • More than half of WHOOP members (52%) tapped WHOOP Coach for individualized recommendations on ways to improve their quality of sleep.
  • When members got morning sunlight, compared to the days they did not, their sleep consistency was higher and they got more sleep, averaging an additional 14 minutes per week.
  • When members practiced daylight eating (consumed all meals during daylight hours), compared to the days they did not, their sleep consistency was also higher and they achieved more quality sleep, averaging an additional 42 minutes per week.
  • Catching zzz's On average, global WHOOP members achieved:
    • Average restorative sleep: 40%
    • Average hours of sleep: 7
    • Average sleep efficiency: 89%
  • Early birds and Night owls Average bedtime and wake time by country:
    • Earliest bedtime: Australia 10:46 p.m., Latest Qatar 1:50 a.m.
    • Earliest wake time: South Africa 6:40 a.m., Latest Qatar 9:38 a.m.
  • Sleep is cultural:
    • The city that never sleeps is Dubai – but in locations known for nightlife, sleep is also poor (Las Vegas, NV; Miami, FL)

Strain - Optimizing Fitness Goes Beyond the Gym

When it comes to enhancing performance around Strain and activity, proper nutrition plays a pivotal role.

  • The top 1% of Strain earners (defined as those members with the highest average Strain) log vegetarian, vegan, and kosher diets more than others. On average, these members are the age of 45.
  • WHOOP members reported using more creatine (+41%) as part of their supplement intake. Protein consumption has also seen an increase in 2023 (+38%).

Activities with multipurpose benefits are gaining popularity.

  • Rucking targets Zone 2 training, which is done at 60-70% of max heart rate, allowing the body to build an aerobic base, enhancing endurance, optimizing fitness, and unlocking performance gains. It’s typically done outdoors where members also reap the benefits of sunlight.
  • Recreational activities are on the rise as people enjoy team fitness. Those that have seen strong adoption in 2023 include pickleball, soccer, cricket, rugby and paddle tennis.

The newest health ambassadors aren’t athletes – they’re performers

  • Stage performance also increased in 2023, with 19% more WHOOP members logging it as a Strain activity year-over-year.
    • Many of the world’s top artists rely on WHOOP to help them choose healthier habits, optimize sleep and travel schedules to be at their best, including record producer, songwriter and DJ Zedd.

“Our community achieved a lot in 2023, and we’re confident that WHOOP will help members achieve even more next year,” said Ahmed. “This feature arrives at a perfect time as our members reflect on their goals and get ready to begin 2024 with new ambitions. WHOOP will be there to help.”

To access and review the WHOOP Community Year in Review, go to: whoop.com/2023-year-in-review. Individual, personalized Year in Review reports will be available to members in the WHOOP app.

Now through December 18, WHOOP is running its Holiday Sale. For a limited time, consumers can take advantage of 10% off prepaid memberships; 12 months for $215 or 24 months for $359. To give the gift of WHOOP this holiday season, go to www.whoop.com.

To make it even more convenient than ever before to access WHOOP, it is available for purchase on Amazon.com, as well as at Best Buy and Dick’s Sporting Goods. WHOOP is currently offering a one-month free trial to help everyone start their journey, available at www.whoop.com.

ABOUT WHOOP

WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP serves professional athletes, Fortune 500 CEOs, executives, fitness enthusiasts, military personnel, frontline workers, and anyone looking to improve their performance. WHOOP Unite is a comprehensive solution dedicated to supporting organizations across a wide range of industries with coaching, organizational insights, and health programs. Studies show WHOOP can positively change behavior, increase sleep, and improve physiological biomarkers. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. The latest round of financing made WHOOP the world's most valuable standalone wearables company. Visit www.whoop.com for more information and connect with WHOOP on Instagram, Twitter, Facebook, LinkedIn, and YouTube.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231211786571/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release

- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least

Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release

-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release

Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou

Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi

Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release

Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye